NCT04251117 — Geneos GNOS-PV02 neoantigen vaccine trial
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
GNOS-PV02, Geneos Therapeutics — with INO-9012 + pembrolizumab in advanced HCC, Phase 1/2
Registry record
| Registry ID | NCT04251117 ↗ |
|---|---|
| Lead sponsor | Geneos Therapeutics |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Active Not Recruiting |
| Indication | HCC |
| Enrollment | 36 participants (target) |
| Start date | 2020-03-01 |
| Primary completion | 2024-11-29 |
| Last registry update | 22 Apr 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04251117), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04251117?
NCT04251117 (GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Geneos Therapeutics.
Is NCT04251117 recruiting?
As of the 2026-04-22 registry update, NCT04251117 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04251117?
The lead sponsor is Geneos Therapeutics.
What condition does NCT04251117 study?
The registered condition is HCC. Primary completion is listed as 2024-11-29.
Are results available for NCT04251117?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04251117.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.